Johnson & Johnson (NYSE:JNJ) Shares Acquired by Inman Jager Wealth Management LLC

Inman Jager Wealth Management LLC boosted its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 30.7% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 7,767 shares of the company's stock after purchasing an additional 1,823 shares during the period. Inman Jager Wealth Management LLC's holdings in Johnson & Johnson were worth $1,288,000 at the end of the most recent reporting period.

Several other hedge funds also recently added to or reduced their stakes in JNJ. TigerOak Management L.L.C. grew its position in Johnson & Johnson by 1.1% in the first quarter. TigerOak Management L.L.C. now owns 12,163 shares of the company's stock valued at $2,017,000 after acquiring an additional 128 shares in the last quarter. Cvfg LLC purchased a new position in shares of Johnson & Johnson in the first quarter valued at $346,000. Live Oak Investment Partners lifted its holdings in Johnson & Johnson by 551.6% in the 1st quarter. Live Oak Investment Partners now owns 8,601 shares of the company's stock worth $1,426,000 after buying an additional 7,281 shares in the last quarter. Alpine Bank Wealth Management purchased a new position in Johnson & Johnson in the 1st quarter valued at about $1,311,000. Finally, Arlington Partners LLC grew its stake in shares of Johnson & Johnson by 249.0% during the first quarter. Arlington Partners LLC now owns 26,128 shares of the company's stock valued at $4,333,000 after acquiring an additional 18,641 shares in the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson Trading Down 0.0%

Johnson & Johnson stock opened at $152.25 on Friday. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.03 and a current ratio of 1.26. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $169.99. The firm's 50-day moving average is $153.85 and its 200-day moving average is $153.69. The company has a market cap of $366.33 billion, a P/E ratio of 16.94, a PEG ratio of 2.31 and a beta of 0.42.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.59 by $0.18. The firm had revenue of $21.89 billion for the quarter, compared to analysts' expectations of $21.65 billion. Johnson & Johnson had a net margin of 24.42% and a return on equity of 33.46%. On average, equities analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th were paid a dividend of $1.30 per share. This is an increase from Johnson & Johnson's previous quarterly dividend of $1.24. This represents a $5.20 dividend on an annualized basis and a yield of 3.42%. The ex-dividend date was Tuesday, May 27th. Johnson & Johnson's dividend payout ratio is presently 57.84%.

Wall Street Analysts Forecast Growth

Several research firms recently commented on JNJ. Bank of America cut their price target on Johnson & Johnson from $171.00 to $159.00 and set a "neutral" rating on the stock in a research note on Thursday, April 10th. Sanford C. Bernstein reaffirmed a "market perform" rating on shares of Johnson & Johnson in a research report on Wednesday, April 16th. Leerink Partnrs cut Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, May 13th. Guggenheim restated a "neutral" rating on shares of Johnson & Johnson in a research note on Wednesday, April 2nd. Finally, The Goldman Sachs Group upgraded shares of Johnson & Johnson from a "neutral" rating to a "buy" rating and increased their price objective for the company from $157.00 to $172.00 in a research note on Wednesday, April 9th. Eleven research analysts have rated the stock with a hold rating, seven have given a buy rating and three have assigned a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $170.88.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.